Strategic Focus Target opportunities in hematologic malignancies and critical diseases where off-the-shelf cellular therapies can bridge patients to long-term recovery, leveraging Nohla’s universal donor platform.

Orphan Drug Leverage Highlight potential for partnerships and co-development in markets seeking Orphan Drug designations, especially for dilanubicel in HSCT, to accelerate regulatory access and reimbursement pathways.

Clinical Leadership Engage with the C-suite and clinical leadership to align on pivotal trials, expansion indications, and adoption pathways, using the recent CMO appointment and early-stage fundraising as credibility signals.

Strategic Partnerships Propose collaborations with academic centers and biotechs to extend the pipeline, especially leveraging the Fred Hutchinson platform, for joint development and manufacturing scale-up.

Funding Readiness Position as a partner for clinical manufacturing and supply chain support in early-stage programs, offering visibility into near-term funding milestones and potential co-investment opportunities from investors familiar with cell therapy.